2,6-Dichloro-4-nitrophenol

We are 2,6-Dichloro-4-nitrophenol CAS:618-80-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 618-80-4
Product Name: 2,6-Dichloro-4-nitrophenol
Other Name:
2,6-Dichloro-4-nitrophenol
2.6-Dichloro-4-nitro-1-hydroxy-benzol
4-Nitro-2,6-dichlorophenol
 
Density: 1.7±0.1 g/cm3
Boiling Point: 285.2±40.0 °C at 760 mmHg
Melting Point: 123-126 °C (dec.)
Molecular Formula: C6H3Cl2NO3
Molecular Weight: 207.999
Flash Point: 126.3±27.3 °C
Exact Mass: 206.949005
PSA: 66.05000
LogP: 2.88
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.639
 
Specification
Appearance: Light brown crystal
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Hexaflumuron CAS: 86479-06-3.
Be used as pesticide intermediate, mainly used in the synthesis of the insecticide Hexaflumuron.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

2,6-Dichloro-4-nitrophenol


Related News: Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.(R)-(+)-9-(2-Hydroxypropyl)Adenine Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes.68737-65-5 These include: high-barrier generic drug substances and commonly used generic drug substances.2-bromoetil etil éter CAS:592-55-2 The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)- View Details
[dimethylamino-(1-oxidopyridin-1-ium-2-yl)sulfanylmethylidene]-dimethylazanium,tetrafluoroborate View Details
4′-Chloro-2′,5′-dimethoxyacetoacetanilide View Details
3,5-dimethyl-4-nitro-1-oxidopyridin-1-ium manufacturer 1-(2-chloroethyl)-4-[3-(trifluoromethyl)phenyl]piperazine,dihydrochloride manufacturer Methyl 4-methoxyacetoacetate manufacturer 2-Bromo-3-nitrotoluene manufacturer Fmoc-Homoarg(Pbf)-OH manufacturer